ClinicalTrials.gg
TerminatedNCT01413087LAPC-BC-819Updated Nov 1, 2019Results posted

Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

A Phase 2 interventional study of Biological/Vaccine: BC-819 in Pancreas, Adenocarcinoma, sponsored by Anchiano Therapeutics Israel Ltd.. Terminated at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-01.

Sponsored by Anchiano Therapeutics Israel Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to Sponsor's decision, only 12 patients were randomized \& completed study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Adenocarcinoma with a site in Israel — none open to participants now, 3 under way, 2 of them phase 3. Adenocarcinoma · Israel.

Enrollment
10th of 10
12 · median 367
Started
2011
the only one that year
Phase 2
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Anchiano Therapeutics Israel Ltd.

Among the 10 studies in Adenocarcinoma with a site in Israel, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 2, and was the 3rd registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

None of the 10 studies in Adenocarcinoma with a site in Israel is open now. The open studies under Adenocarcinoma, anywhere →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Adenocarcinoma with a site in Israel as a file.
02

Study summary

This is a multicenter, open label, randomized, phase 2b study, designed to evaluate the safety and efficacy of patients with locally advanced pancreatic adenocarcinoma following intratumoral administration of BC-819 and intravenously administered gemcitabine. Intratumoral injections of BC-819 will be performed using endoscopic ultrasound (EUS).

Primary Objective: To assess the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival.

Secondary Objectives: To compare the effects of intratumoral injection of BC-819 administered in combination with intravenous gemcitabine vs. intravenous gemcitabine alone on:

Overall survival, Response rate, Resectability of the target tumor lesion, Quality of life, Safety, Serological Tumor Marker: CA 19-9, Duration of response, Failure-free survival

Read the detailed description

BC-819 (also known as DTA-H19) is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. This is a Targeted Cancer Therapy; DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment.

03

Conditions studied

  • Pancreas, Adenocarcinoma

Keywords

  • Pancreatic cancer
  • Gemcitabine
  • BC-819
  • Adenocarcinoma
  • Resectable
  • H19 gene
  • DTA-H19
  • BioCancell
  • inodiftagene vixteplasmid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females > 18 years of age
  2. If female, must not be pregnant or nursing; women of must practice a medically approved method of
  3. If male, must practice a medically approved method of contraception if have a partner of childbearing potential
  4. or cytologically confirmed adenocarcinoma of the exocrine pancreas
  5. Locally advanced pancreatic cancer (LAPC) that is clinically unresectable as defined in the NCCN Guidelines
  6. performance status (KPS) ≥ 70% at baseline
  7. Adequate hematological, renal, and hepatic function

    • count ≥ 100,000/mm3
    • (ANC) ≥ 1500/mm3
    • ≥ 10.0 g/dL (may be achieved by transfusion)
    • Creatinine (≤ 1.5 x )
    • , AST (≤ 1.5 x ULN)
    • Total (≤ 1.5 x ULN)
  8. Have a target tumor lesion in the pancreas ≤ 6 cm in diameter that is accessible for intratumoral administration by EUS guidance as determined by the physician performing the EUS injection
  9. Have a specimen that is positive for H19 expression (grade 2 or greater staining determined by a pathologist). H19 expression can be determined based on a biopsy specimen collected before study participation, if available.
  10. No prior diagnosis of within 3 years except for curatively treated non-melanoma skin or in situ malignancies
  11. Able to comply with the protocol procedures
  12. Able and willing to provide written (signed) to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Have distant spread (such as liver or lung metastases), peritoneal spread or malignant ascites. Regional lymph node involvement may be considered in accordance with the PI's judgment
  2. Received any prior therapy for the treatment of pancreatic (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or , other than up to4 single doses of gemcitabine chemotherapy.Patients who received prior gemcitabine will only be eligible, if they enter the study without evidence of disease progression.
  3. Known (HIV) or virus (HCV) or virus (HBV) infection
  4. Have pancreatitis within 12 weeks of treatment
  5. Have a clinical history of significant coagulopathy
  6. Have a medical condition for endoscopic-guided delivery and/or for IV administration of Gemcitabine or any intercurrent medical illness or other medical condition that would in the judgment of the investigator compromise patient safety or the objectives of the study
  7. Have participated in any experimental therapeutic research study with an unapproved drug within 4 weeks of the screening visit
  8. Patients who require ongoing anticoagulation for pre-existing conditions, e.g., thrombophlebitis, pulmonary embolus or atrial fibrillation
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    8 mg BC-819 and Gemcitabine

    gemcitabine dose of 1000mg/m2 + 8 mg of BC-819

    Biological: Biological/Vaccine: BC-819

  • Experimental
    12 mg BC-819 and Gemcitabine

    gemcitabine dose of 1000mg/m2 + 12 mg of BC-819

    Biological: Biological/Vaccine: BC-819

Interventions

  • BiologicalBiological/Vaccine: BC-819

    Drug pages: Biological Products · Inodiftagene vixteplasmid

    Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression. After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)

    Also known as: DTA-H19, inodiftagene vixteplasmid

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    To compare the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival. PFS was defined as the time from the date of consent until objective tumor progression or death. Median PFS by Kaplan-Meier analysis was used for evaluation. The target tumor lesion was identified and the longest diameter of the target lesion was measured according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. For disease evaluations after treatment, scans conducted at baseline that were used for tumor measurements were repeated.

    Time frame: 24 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was calculated from the date of consent until death due to any cause.

    Time frame: 24 months

  2. Response Rate of Target Lesion

    Response rate will be assessed both for the primary target tumor lesion alone and overall, including development of metastases. Target tumor lesions are identified and the longest diameter of the target lesion is measured by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also show an increase of at least 5 mm. Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: 8 weeks

  3. Resectability of the Target Tumor Lesion

    Resectability of the target tumor lesion was determined by CT/MRI as defined in the National Comprehensive Cancer network (NCCN) guidelines. Resectable tumors have no arterial tumor contact (celiac axis \[CA\], superior mesenteric artery \[SMA\], or common hepatic artery \[CHA\]) and no tumor contact with the superior mesenteric vein (SMV) or portal vein (PV) or ≤180° contact without vein contour irregularity. \*Not Applicable refers to another clinically significant abnormality that interfered with resectability determination of the target tumor lesion.

    Time frame: an average of 16 weeks

  4. Quality of Life (QoL) Assessed by Karnofsky Performance Status (KPS)

    Quality of life will be assessed by the The Karnofsky Performance Status (KPS) Index. KPS scores over time will be compared to those at baseline and changes from baseline will be presented. KPS scores are on a scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100) of 0 (dead) to 100 (Normal no complaints; no evidence of disease).

    Time frame: Screening, Visit 4 (post gemcitabine induction), Visit 9 (5 weeks), Visit 13 (9 weeks)

  5. Quality of Life Using the Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire

    The FACT-G is a 27-item compilation of general questions divided into 4 primary QoL domains: physical well-being, social/family well-being, emotional well-being and functional well-being. The total FACT-G scores will be summarized by descriptive statistics (e.g., n, mean, median, standard deviation and range). The individual FACT-G score will be presented by frequency and percentage. Scores range from 0-108. High total scores represent better general QoL.

    Time frame: Screening, Visit 4 (post gemcitabine induction), Visit 9 (5 weeks), Visit 13 (9 weeks), every 6 months after Visit 13

  6. Serological Tumor Marker: CA 19-9

    Serum was collected for quantitative measurement of CA 19-9.

    Time frame: 24 months

  7. Extent of Exposure - Gemcitabine Total Exposure (g)

    Measured by the average and median number of exposure of the patients to BC-819 and gemcitabine.

    Time frame: 24 months

  8. Extent of Exposure - Gemcitabine Total Number of Treatments

    Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.

    Time frame: 24 months

  9. Extent of Exposure - BC-819 Total Exposure (mg)

    Measured by the average and median exposure of the patients to BC-819 and gemcitabine.

    Time frame: 24 months

  10. Extent of Exposure - BC-819 Total Number of Treatments

    Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.

    Time frame: 24 months

07

Results

Posted Nov 1, 2019

Participant flow

Participant flow — Overall Study
Milestone8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Started66
Completed66
Not completed00

Outcome measures

PrimaryProgression-free Survival (PFS)

To compare the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival. PFS was defined as the time from the date of consent until objective tumor progression or death. Median PFS by Kaplan-Meier analysis was used for evaluation. The target tumor lesion was identified and the longest diameter of the target lesion was measured according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. For disease evaluations after treatment, scans conducted at baseline that were used for tumor measurements were repeated.

Time frame:
24 months
Reported as:
Median · months
Progression-free Survival (PFS)
months8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Progression-free Survival (PFS)9.3 (2.6 to 26.3)7.6 (6.3 to 10.7)
Statistical analysis
  • 8 mg BC-819 and Gemcitabine vs 12 mg BC-819 and Gemcitabine · Log Rank · p = 0.483P value by log-rank test for the difference between treatment groups
SecondaryOverall Survival (OS)

OS was calculated from the date of consent until death due to any cause.

Time frame:
24 months
Reported as:
Median · years
Overall Survival (OS)
years8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Overall Survival (OS)9.9 (5.4 to 26.4)8.5 (6.8 to NA)
Statistical analysis
  • 8 mg BC-819 and Gemcitabine vs 12 mg BC-819 and Gemcitabine · Log Rank · p = 0.992P value by log-rank test for the difference between treatment groups
SecondaryResponse Rate of Target Lesion

Response rate will be assessed both for the primary target tumor lesion alone and overall, including development of metastases. Target tumor lesions are identified and the longest diameter of the target lesion is measured by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also show an increase of at least 5 mm. Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Response Rate of Target Lesion
Participants8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Complete Response00
Partial Response10
Stable Disease26
Progressive Disease10
Inevaluable - Missing Postbaseline Scan20
SecondaryResectability of the Target Tumor Lesion

Resectability of the target tumor lesion was determined by CT/MRI as defined in the National Comprehensive Cancer network (NCCN) guidelines. Resectable tumors have no arterial tumor contact (celiac axis \[CA\], superior mesenteric artery \[SMA\], or common hepatic artery \[CHA\]) and no tumor contact with the superior mesenteric vein (SMV) or portal vein (PV) or ≤180° contact without vein contour irregularity. \*Not Applicable refers to another clinically significant abnormality that interfered with resectability determination of the target tumor lesion.

Time frame:
an average of 16 weeks
Reported as:
Count of participants · Participants
Resectability of the Target Tumor Lesion
Participants8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Not Resectable56
Not Applicable*10
SecondaryQuality of Life (QoL) Assessed by Karnofsky Performance Status (KPS)

Quality of life will be assessed by the The Karnofsky Performance Status (KPS) Index. KPS scores over time will be compared to those at baseline and changes from baseline will be presented. KPS scores are on a scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100) of 0 (dead) to 100 (Normal no complaints; no evidence of disease).

Time frame:
Screening, Visit 4 (post gemcitabine induction), Visit 9 (5 weeks), Visit 13 (9 weeks)
Reported as:
Median · score on a scale
Quality of Life (QoL) Assessed by Karnofsky Performance Status (KPS)
score on a scale8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Screening90 (80 to 100)90 (80 to 100)
Visit 4 (pre-randomization)90 (90 to 90)85 (80 to 100)
Visit 9 (Week 5)80 (80 to 90)90 (80 to 90)
Visit 13 (Week 9)80 (80 to 90)90 (80 to 90)
SecondaryQuality of Life Using the Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire

The FACT-G is a 27-item compilation of general questions divided into 4 primary QoL domains: physical well-being, social/family well-being, emotional well-being and functional well-being. The total FACT-G scores will be summarized by descriptive statistics (e.g., n, mean, median, standard deviation and range). The individual FACT-G score will be presented by frequency and percentage. Scores range from 0-108. High total scores represent better general QoL.

Time frame:
Screening, Visit 4 (post gemcitabine induction), Visit 9 (5 weeks), Visit 13 (9 weeks), every 6 months after Visit 13
Reported as:
Mean · units on a scale
Quality of Life Using the Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire
units on a scale8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Screening71.8 ± 11.881.9 ± 14.0
Max change from baseline-1.3 ± 18.5-2.5 ± 18.8
SecondarySerological Tumor Marker: CA 19-9

Serum was collected for quantitative measurement of CA 19-9.

Time frame:
24 months
Reported as:
Mean · U/mL
Serological Tumor Marker: CA 19-9
U/mL8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Screening1025.9 ± 1090.6587.7 ± 340.1
Nadir value369.8 ± 511.7149.1 ± 97.0
Change at Nadir-656.1 ± 887.7-438.6 ± 252.2
SecondaryExtent of Exposure - Gemcitabine Total Exposure (g)

Measured by the average and median number of exposure of the patients to BC-819 and gemcitabine.

Time frame:
24 months
Reported as:
Mean · g
Extent of Exposure - Gemcitabine Total Exposure (g)
g8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Extent of Exposure - Gemcitabine Total Exposure (g)20.1 ± 9.521.3 ± 11.9
SecondaryExtent of Exposure - Gemcitabine Total Number of Treatments

Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.

Time frame:
24 months
Reported as:
Mean · number of treatments
Extent of Exposure - Gemcitabine Total Number of Treatments
number of treatments8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Extent of Exposure - Gemcitabine Total Number of Treatments17.3 ± 14.915.3 ± 12.7
SecondaryExtent of Exposure - BC-819 Total Exposure (mg)

Measured by the average and median exposure of the patients to BC-819 and gemcitabine.

Time frame:
24 months
Reported as:
Mean · mg
Extent of Exposure - BC-819 Total Exposure (mg)
mg8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Extent of Exposure - BC-819 Total Exposure (mg)68.0 ± 29.8118.0 ± 41.2
SecondaryExtent of Exposure - BC-819 Total Number of Treatments

Measured by the average and median number of treatments of the patients to BC-819 and gemcitabine.

Time frame:
24 months
Reported as:
Mean · number of treatments
Extent of Exposure - BC-819 Total Number of Treatments
number of treatments8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Extent of Exposure - BC-819 Total Number of Treatments10.7 ± 8.411.2 ± 6.0

Adverse events

Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
8 mg BC-819 and Gemcitabine0/6 (0%)5/6 (83.3%)5/6 (83.3%)
12 mg BC-819 and Gemcitabine1/6 (16.7%)5/6 (83.3%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
Event8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
Bile duct obstructionHepatobiliary disorders1/62/6
PneumoniaInfections and infestations1/60/6
Generalized EdemaGeneral disorders1/60/6
Gastrointestinal obstructionGastrointestinal disorders1/60/6
Clostridium difficile colitisInfections and infestations1/60/6
DehydrationMetabolism and nutrition disorders1/60/6
Epigastric painGastrointestinal disorders1/60/6
Frequent bowel movementGastrointestinal disorders1/60/6
DuodenitisGastrointestinal disorders1/60/6
Stent malfunctionProduct Issues0/61/6
Most frequent other events
Showing 10 of 43
Most frequent other events
Event8 mg BC-819 and Gemcitabine12 mg BC-819 and Gemcitabine
NauseaGastrointestinal disorders4/64/6
FatigueGeneral disorders4/61/6
VomitingGastrointestinal disorders3/61/6
ConstipationGastrointestinal disorders3/61/6
Increased blood bilirubinInvestigations0/63/6
Decreased appetiteMetabolism and nutrition disorders3/61/6
NauseaGastrointestinal disorders3/63/6
Abdominal painGastrointestinal disorders2/61/6
DiarrheaGastrointestinal disorders2/61/6
AstheniaGeneral disorders2/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)8 mg BC-819 and Gemcitabine12 mg BC-819 and GemcitabineTotal
Mean72.2 ± 6.762.2 ± 13.067.4 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)8 mg BC-819 and Gemcitabine12 mg BC-819 and GemcitabineTotal
Female415
Male257
Race (NIH/OMB)
Race (NIH/OMB)(Participants)8 mg BC-819 and Gemcitabine12 mg BC-819 and GemcitabineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White5611
More than one race000
Unknown or Not Reported000
08

Study locations

9 sites
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Joe Arrington Cancer Research & Treatment Center
    Lubbock, Texas 79410, United States
  • Carmel Medical Center
    Haifa, Israel
  • Rambam Medical Center
    Haifa, Israel
  • Hadassah Medical Organization
    Jerusalem, Israel
  • Meir Medical Center
    Kfar Saba, Israel
  • Galil Maaravi
    Nahariya, Israel
  • Tel Aviv Medical Center
    Tel Aviv, Israel
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2011 to primary completion in Jan 2013, 16 months.

Results were first posted in Nov 2019, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2011
First posted
Aug 10, 2011
StartActual
Sep 2011
Primary completionActual
Jan 2013
CompletionActual
May 2014
Results first posted
Nov 1, 2019
Last update
Nov 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01413087
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Responsible party
Sponsor
First posted
Aug 10, 2011
Start date
Sep 2011
Primary completion
Jan 2013
Completion
May 2014
Results posted
Nov 1, 2019
Last update
Nov 1, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Biological Products · Inodiftagene vixteplasmid

Start the discussion